Ultragenyx Pharmaceutical Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Ultragenyx Pharmaceutical Inc. on October 8, 2020. The report addresses Item 5.02 regarding the departure of certain officers and the appointment of new officers, specifically concerning the Chief Financial Officer (CFO) role.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on executive personnel changes.
Material Changes
- CFO Appointment Accelerated: The effective date for Mardi C. Dier's appointment as Executive Vice President and Chief Financial Officer was moved forward from November 2, 2020, to October 12, 2020.
- Outgoing CFO Transition: Shalini Sharp ceased serving as CFO on October 12, 2020. She will continue as Executive Vice President, Finance until November 2, 2020, to assist with the transition.
- Extended Support: Ms. Sharp will remain an employee providing transition-related support until May 2, 2021, or an earlier mutually agreed date.
- Agreement Amendments: The Company executed Amendment No. 1 to Ms. Dier's offer letter and Amendment No. 2 to Ms. Sharp's Transition Letter Agreement to reflect these changes.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on business performance, or discussion of risks and contingencies. The primary purpose is to disclose the modified timeline for the CFO transition.
Key Facts for Investor Verification
- Verify the exact effective date of Mardi C. Dier's tenure as CFO (October 12, 2020).
- Confirm the duration of Shalini Sharp's continued employment and transition support role (through May 2, 2021).
- Review the full text of the Offer Letter Amendment (Exhibit 10.1) and Transition Agreement Amendment (Exhibit 10.2) for specific compensation or contractual terms not detailed in this summary.